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MVS1-1
LIMITED LIVER RESECTION FOR
TYPE 1, 2 HILAR
CHOLANGIOCARCINOMA
Itaru Endo
Yokohama City University, Japan
Surgical treatment of perihilar cholangiocarcinoma
remains a challenge even for a relatively large scale
clinical experience managing this disease. En-bloc hemi-
hepatectomy with caudate lobectomy has been estab-
lished as the standard procedure for Bismuth type II,
III tumor. However, extent of liver resection should be
reduced when patient’s liver function or general condi-
tion is poor. In such instances, achieving an R0 resec-
tion is sometimes difficult because of the anatomic
constraints of the hepatic hilum. To achieve R0 resec-
tion, it is essential to make a precise preoperative diag-
nosis of tumor extension using several imaging
modalities. Also, such limited resection often require
vascular reconstruction to obtain cancer free radial
margins if direct vascular invasion was suspected by
MPR images. Virtual 3D simulation helps surgeons to
achieve R0 resection with minimized risk of postopera-
tive morbidities. If R0 resection could be achieved,
long-term results of the patients who underwent limited
resection is equal to that of extended resection. Limited
liver resection may be acceptable as an alternative
treatment for type I, II hilar cholangiocarcinoma with
poor condition.
MVS1-2
RIGHT TRISECTIONECTOMY WITH
CAUDATE LOBECTOMY FOR TYPE IV
HILAR CHOLANGIOCARCINOMA
WITH SPECIAL REFERENCE TO LEFT
PORTAL PLANE DISSECTION
Dong Wook Choi
Samsung Medical Center, Sungkyunkwan University,
Korea
Best surgical strategy for hilar cholangiocarcinoma is
combined hepatic resection including caudate lobec-
tomy with extra-hepatic bile duct resection. However
optimal type of hepatic resection remained to be deter-
mined. Especially, it is known that type IV hilar cho-
langiocarcinoma is contraindication for resection
because of difficulty in pathologically curative resec-
tion.
In my video presentation, I’ll show right trisectionecto-
my with caudate lobectomy with special reference to
left portal plane dissection for type IV hilar cholagio-
carcinoma.
I use bilateral subcostal incision with median extension
method for skin incision. After through exploration of
abdominal cavity to detect the hidden metastasis, left
hepatic artery was identified and preserved. Then, the
dissection of hepatoduodenal ligament was performed
to dissect the lymph node and perivascular soft tissues
following common bile duct transection at the supra-
pancreatic level. During upward dissection of bile duct
and soft tissue including lymph node, right hepatic
artery and right portal vein with several small portal
vein branches to caudate process and Spigelian lobe
were dissected. Following complete dissection of hepa-
toduodenal ligament, right hemi-liver and caudate were
completely mobilized from IVC after right hepatic vein
division. Then, parenchymal dissection of the liver
along left portal plane was performed using CUSA and
middle hepatic vein was divided at the level of vena
cava, also. Finally bile duct to segment 4 was identified
and left bile duct was divided at the level of the left
side of the umbilical portion, after several small portal
vein to segment 4 were identified and divided,. Hepati-
cojejunostomy was constructed with interrupt suture
using 5-0 vicryl.
I believe that this technique will be useful for better
survival outcome through achieving higher pathologically
curative resection rate for hilar cholangiocarcinoma.
MVS1-3
LEFT-SIDED HEPATECTOMY FOR
TYPE 3B OR 4 HILAR
CHOLANGIOCARCINOMA
Katsuhiko Uesaka
Shizuoka Cancer Center, Japan
Although left-sided hepatectomy with caudate lobec-
tomy is one of the standard procedures for surgical
resection of perihilar cholangiocarcinoma, it is a techni-
cally demanding operation and is associated with some
difficult technical points.
A very complicated surgical procedure, left trisectionec-
tomy and caudate lobectomy of the liver, pancreatico-
duodenectomy, and combined resection of the right
hepatic artery (RHA) for perihilar cholangiocarcinoma
with supra-portal posterior sectional artery (Apost), is
presented by video.
Case: The patient was a 73 year-old woman. Preopera-
tive images showed a Bismuth type IV biliary stricture
and invaded RHA. The right portal vein branched into
the ventral twig of the right anterior superior branch
(P8a) and the right posterior sectional vein (Ppost) plus
dorsal twig of the right anterior superior branch (P8c).
The invaded RHA ramified into the ventral twig of the
right anterior superior branch (A8a) and Apost plus
dorsal twig of the right anterior superior branch (P8c)
which coursed cranially and dorsally to P8a. After
branching off the A8c, Apost coursed caudally and
ventrally to P8c.
Video: Ppost was exposed in the Rouviere sulcus fol-
lowed by taping of the right portal vein and portal
trunk, and ligation and division of P8c. Superior mes-
enteric vein was exposed, and the pancreas neck was
taped. Stomach was divided at the level of the gastric
angle. The common hepatic, proper hepatic and gastro-
duodenal arteries (GDA) were taped, and left and
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meddle hepatic arteries were ligated. GDA was dis-
sected up to the level of the right gastroepiploic artery
(RGEPA). Left portal vein was ligated and divided.
Jejunum was divided and the pancreas head was dis-
sected from the superior mesenteric artery and vein.
After mobilization of the caudate lobe, liver resection
was started. During liver resection, P8c and A8c were
ligated and divided. Following dissection of the com-
mon trunk of the middle and left hepatic veins, the
right posterior sectional duct, Apost, and PHA were
divided, and finally pancreas was dissected. Following
mcroscopic reconstruction of Apost with RGEPA, pan-
creaticojejunostomy, hepaticojejunostomy, and gastro-
jejsunostomy were performed. Operation time was 13
hours and 38 minutes, and bleeding amount was 1888
ml. She was discharged from hospital 40 days after sur-
gery.
To perform this complicated procedure successfully,
comprehension of 3-dimensional hilar anatomy, meticu-
lous technique for dissection of hepatic arteries and
portal branches, and prevention of pancreatic fistula
are mandatory.
MVS1-5
COMBINED ARTERIAL AND VENOUS
RESECTION FOR HILAR
CHOLANGIOCARCINOMA
Masaru Miyazaki
Chiba University, Japan
Hilar cholangiocarcinoma involving hilar vasculature of
the portal vein and hepatic artery has been usually not
indicated to surgical resection before. Some aggressive
surgeons have tried to perform the aggressive combined
vascular resection for advanced hilar cholangiocarcinoma.
We have reported the result of combined vascular
resection for hilar cholangiocarcinoma in 2007 (Sur-
gery.141:581-8) .that the portal vein resection could be
safely carried out and might bring about a beneficial
effect on the prognosis of the patients, but no suffi-
ciently promising effect on the prognosis in the patients
with combined hepatic arterial resection. Therefore,
since then we have carefully selected the patients for
combined portal vein and hepatic artery resection for
hilar cholangiocarcinoma involving these vessels.
We have performed combined vascular resection for
hilar cholangiocarcinoma with the portal vein in 70
patients, and the hepatic artery in 13 patients, and also
IVC in 8 patients.
Combined the hepatic artery and portal vein resection
was done in 12 patients. When the combined hepatic
artery and portal vein resection was done for hilar cho-
langiocarcinoma, hepatic ischemic damage due to the
inflow interruption of both hepatic arterial and portal
venous blood flow should be avoided as much as possi-
ble. Therefore, we have avoided the simultaneous both
inflow interruption of the hepatic artery and portal vein
in the combined hepatic artery and portal vein resec-
tion. The portal vein resection and reconstruction is
usually done prior to hepatic arterial resection and
reconstruction. It means that the hepatic arterial blood
flow into the remnant liver could be maintained during
the portal vein reconstruction, and also the portal
venous blood flow could be preserved during the hepa-
tic arterial reconstruction. Therefore, the remnant liver
could not be severely damaged by the hepatic ischemic
injury induced by the combined interruption of hepatic
arterial and portal vein blood flow.
The combined vascular resection of the portal vein and
hepatic artery might be able to be done for obtaining a
curative resection in patients with locally advanced
hilar cholangiocarcinoma. The operation technique of
combined hepatic arterial and portal vein resection is
presented in this presentation.
MVS1-6
LEFT TRISECTIONECTOMY WITH PV
& HA RESECTION BY LAPAROSCOPY
Go Wakabayashi
Iwate Medical University, Japan
Laparoscopy-assisted major hepatectomy is safely
applied to donor hepatectomy and hepatectomy for the
hilar cholangiocarcinoma. Precise skeletonization of the
hepatoduodenal ligament and a safe and reliable hepa-
ticojejunostomy are essential for resection of hilar cho-
langiocarcinoma. We present a case by video to
describe laparoscopy-assisted left trisectionectomy for
hilar cholangiocarcinoma of Bismuth–Corlette classifi-
cation type IV with both portal vein and hepatic artery
reconstructions.
Case presentation:A 68 y/o female patient was diag-
nosed with hilar cholangiocarcinoma located at the
bifurcation and invaded to both the portal vein and the
hepatic artery. Laparoscopy-assisted left trisectionecto-
my with S1 resection was planned with both portal vein
and hepatic artery reconstructions.
Operative procedure: After a full mobilization of the left
lateral sector, the Spiegel lobe was carefully detached
from the inferior vena cava under pneumoperitoneum.
A 10cm upper midline incision was made and a Pen-
rose drain was placed between the middle hepatic vein
(MHV) and the right hepatic vein (RHV) for hanging
the transection line. The hepatoduodenal ligament was
precisely skeletonized with lymph node dissection
through the mini-laparotomy. Parenchymal transection
started from the root of RHV and finished around the
right posterior portal pedicle at the hilum. The poster-
ior branch of the right portal vein and the right hepatic
artery were taped and the posterior bile ducts were
divided. The duct margin was cancer free. The portal
vein was resected and the posterior branch was anasto-
mosed with the main portal branch. The left trisection-
ectomy with S1 resection was completed after the
hepatic artery resection. The posterior branch of the
right hepatic artery was anastomosed with the main right
hepatic artery using a magnifier loupe. Hepaticojejunos-
tomy was performed through mini-laparotomy.
Operative time was 682 min and blood loss was 640
ml. The patient was discharged on the 42nd post-opera-
tive day after having a minor leakage of the hepati-
cojejunostomy.
We applied laparoscopy-assisted major hepatectomy
safely for the treatment of hilar cholangiocarcinoma.
This minimal access surgery is useful for even HA and
PV reconstruction and hepaticojejunostomy as well.
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MVS2-1
LIVER RESECTION COMBINED WITH
REMOVAL OF TUMOR THROMBUS
EXTENDING TO THE RIGHT ATRIUM
Keiichi Kubota
Dokkyo Medical University, Japan
Hepatocellular carcinoma (HCC) characteristically
invades hepatic veins and develops tumor thrombus
(TT) in the inferior vena cava (IVC). The IVC-TT
occasionally extends to the right atrium, causing pul-
monary embolism and edema of the lower part of the
body, and presents clinical difficulty in treatment. In
this presentation, surgical technique for HCC with
IVC-TT extending to the right atrium is described.
Patients: Three out of 679 patients, who underwent
hepatic resection for HCC in my department between
April 2000 and July 2013, had HCC with IVC-TT
extending to the right atrium. There were two males
and one female with a median age of 70 years (57-71)
and a median ICG15 of 16% (5-31). All patients
received TAE before surgery.
Surgical techniques: The J-shape incision was employed
for opening the abdomen and thoracic cavity. Supra-
hepatic IVC was encircled by opening the pericardial
cavity and infra-hepatic IVC was encircled at the site
cranial to the entrance of renal veins. After dividing
the liver, the anterior surface of IVC and the right or
left hepatic vein containing TT were exposed com-
pletely. Intraoperative ultrasound demonstrated IVC-
TT extending to the right atrium. By pulling the
resected liver towards the caudal side, the IVC-TT was
withdrawn from the right atrium to the IVC and the
caudal part of the right atrium could be clamped by a
forceps. The infra-hepatic IVC was also clamped.
Under total clamping, the IVC was incised and the TT
was removed. In two patients, the TT adhered to the
IVC wall, requiring partial resection of the wall and
repair using a horse-pericardium patch. In one patient,
the IVC could be closed by direct suture.
All patients successfully underwent hepatic resections
with removal of IVC-TT without employing heart-lung
machine. Extending posterior segmentectomy was per-
formed in two and lateral segmentectomy with caudate
lobe resection in one. The median values of Pringle
time for hepatic resection, total clamping time, bleeding
amount and operation time were 36 minutes (30-88), 23
minutes (7-24), 2986 ml (2474-14500) and 365 minutes
(362-494), respectively. The postoperative courses were
uneventful. However, in all patients, HCC recurred in
the remnant liver and lung. TAE was performed for
recurrence in the liver and Nexavar was administered
systemically. Two patients died of HCC on the 286th
and 400th postoperative day, respectively. One patient
is alive on the 753rd postoperative day with administra-
tion of Nexavar.
Although the results of hepatic resection for HCC with
IVC-TT extending to the right atrium are not satisfied,
the surgical treatment prevents sudden death due to
pulmonary embolism and contributes to prolonging
overall survival period by combining TAE and Nexavar
administration.
MVS2-2
MODIFIED RIGHT-LOBE LDLT WITH
IVC REPLACEMENT AND ATRIO-
CAVAL ANASTOMOSIS FOR BUDD-
CHIARI SYNDROME
Sung-Gyu Lee
Asan Medical Center, Ulsan University, Seoul, Korea
Budd-Chiari syndrome is associated with a predisposi-
tion to thrombosis or stenosis of the major hepatic
veins and/or IVC at any point proximal to the right
atrium. According to the location of IVC stenosis, a
different approach such as cavoplasty only in both
sides or IVC replacement with cadaveric donor’s IVC
or artificial vascular graft might be necessary. Under
those situation, cavoplasty on both sides is not practi-
cal because dissection of the retrohepatic IVC results in
a lot of bleeding, and often the paper-thin IVC wall is
prone to be torn away and unable to use without ve-
noplasty or reinforcement. In addition, exposure of the
suprahepatic vena cava to the junction of the right
atrium is not feasible without sternotomy or at least
pericardiotomy, and the outcomes of reuse of fibrotic
suprahepatic IVC segment after cavoplasty is still ques-
tionable. At our institution, IVC replacement with a
large-caliber artificial interposition vascular graft
between right atrium and infrahepatic IVC during
LDLT was first introduced in 2006 for Budd-Chiari
syndrome with diseased stenotic retrohepatic vena cava,
and thrombotic obstruction of the suprahepatic IVC
extends almost to the junction of the right atrium and
intrapericardiac IVC. All 6 patients who underwent
IVC replacement between atrium and suprarenal IVC
at the AMC are alive at median follow-up of 65
months (range, 14-77 months) without IVC stenosis or
thrombotic complications.
MVS2-3
LIVER RESECTION AND
RECONSTRUCTION FOR IVC AND
HEPATIC VEIN INVOLVEMENT
Peter Lodge
Leeds Teaching Hospitals NHS Trust, United Kingdom
Complex liver resection for tumors involving the IVC
and hepatocaval confluence remains challenging. This
video examines several cases to illustrate variations in
surgical approaches to this complex problem.
Several liver resections are shown, starting with tumors
that peel off the IVC up to tumors that involve the
IVC and hepatic veins. The use of in situ hypothermic
perfusion and veno-venous bypass during this surgery
is highlighted.
The techniques illustrate how difficulties can be over-
come.
Although these cases remain a surgical challenge, sev-
eral aproaches to these difficult tumors can deliver
good results,
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MVS2-4
EX-SITU LIVER RESECTION:
TECHNICAL REFINEMENT IN THE
PARTIAL LIVER TRANSPLANTATION
ERA
Umberto Cillo
Padova University, Italy
Surgical R0 resection, when feaseable, is the best thera-
peutic tool for patients with several primitive and sec-
ondary hepatic tumors.
In patients with colorectal liver metastasis (CRLM) a
5-year overall survival rate (OSR) of 35 to 58% is
reported after hepatectomy with curative intent.
Surgery showed an improvement in outcome also in
patient with intrahepatic (I-CCA) and hilar cholangio-
carcinoma (H-CCA).
Resected patient with I-CCA classificated as locally
advanced or extensive according to SEER, demon-
strated a statistically significative improvement in 1-
and 5-years OSR compared to controls (77% vs. 32%
and 20% vs. 4% for locally advanced; 66% vs. 28%
and 13% vs. 3% for extensive disease).
Extended R0 liver resections are the best treatment
option for H-CCA with reported 5-years survival of 11
to 41% too, while in R1 resection OSR is reported to
be less then 10% at 5-years.
Over the last decade, criteria for resectability of CRLM
and CCA have been expanded and there has been a
paradigm shift.
Nowadays resectability is defined no longer by “what
can be removed” but according to “what has to remain”
after surgery with particular focus on radicality, vascular
in- and out-flow, biliary drainage and future remnant
liver volume.
According to this new concept, gross vascular invasion,
limited tolerance of the liver against warm ischemia
and critical tumor location have proven to be major
factors affecting resectability of liver tumors.
In particular, patients with tumor involvement of all
the three suvrahepatic veins (HV) and the inferior vena
cava (IVC) with or without contact with the glissonian
carrefour are diffusely considered unsuitable for surgi-
cal liver resection.
A number of international series, although numerically
limited, have shown that ex situ liver resection (in vivo/
ex vivo) may offer a chance to treat these otherwise un-
resectable liver tumors in highly selected patients. How-
ever these series report often an extremely high peri-
operative mortality (up to more than 50%). We report
our initial Center experience with ex-situ liver resection
introducing some technical refinements significantly
contributing to our zero 90-days mortality.
Eight patients (mean age 52,6  15.8 years; 5 females
and 3 males) undergoing ex-situ liver resection from
February 2011 to May 2013 are reported.
All patients were considered not resectable with the
conventional surgical approach.
Future remnant liver volume of at least 40% was
required in order to minimize the risk of post-operative
liver failure.
Resections were carried out for cholangiocarcinoma (n.
4), liver metastases (n. 3), hepatocellular carcinoma (n. 1).
Ex-situ liver resection we had performed included 4 ex-
vivo and 4 ante-situm procedures. Hypothermic contin-
uous perfusion with 4°C Celsior solution has been
employed in all patients. A new technique excluding
the veno-venous bypass has been adopted in 3 out of 8
procedures. All patients had their resudual HV recon-
structed with homografts. All IVC were restored, 7
using a tube graft and 1 an homograft.
Mean operative time was 731 minutes, median anhepat-
ic phase duration was 100 minutes. Median ICU stay
was 6 days. Median hospitalization was 32 days.
No patient had evidence of postoperative liver failure;
4 patients developed grade IIIb complication according
to Dindo-Clavien and required reintervention. There
was no 90-day mortality. During a median follow-up of
265 days one patient died due to disseminated multi-
drug resistent infection (Klebsiella Pneumoniae) at 165
days and 1 patient from recurrent disease at 247 days.
Six patiens are alive, 4 without evidence of recurrent
disease.
Ex-situ liver resection represents a potentially impor-
tant therapeutic tool to treat otherwise unresectable
liver malignancies among carefully selected patients.
These techniques require extremely demanding techni-
cal skills which have to be acquired in the field of liver
surgery, included transplantation. The avoidance of
V-V by pass, when feasible, and outflow reconstruction
techniques deriving from LDLT experience have the
potential to significantly improve feasibility and results
of this demanding procedure.
MVS2-6
ROBOT-ASSISTED EXTENDED LEFT
HEPATECTOMY INCLUDING CAUDATE
LOBE WITH RETROGASTRIC
INTRAHEPATICOJEJUNOSTOMY FOR
CHOLANGIOCARCINOMA
P.C. Giulianotti
University of Illinois at Chicago, USA.
Cholagiocarcinomas (ChC) of the biliary bifurcation
are very challenging, requiring multimodality treat-
ments including liver tranplantation. The minimally
invasive (MIS) approach of this tumor respecting onco-
logical principles can be attempted. We present a case
of a ChC of the hepatic ducts carrefour that was com-
pletely resected through a MIS approach.
A 72 years old male was referred for a ChC of the
hepatic ducts carrefour. Preoperative CT, MRI and
ERCP with biopsy sampling of the lesion were per-
formed. A robotic assisted approach with resection of
the tumor through an extended left hepatectomy with
transmesocolonic retrogastric intrahepaticojejunostomy
is presented.
In the OR, after intra-operative diagnostic laparoscopic
staging, camera port positioning and visualization of
the hilum, trocar set up was completed and ultrasound
of liver was performed. The hepatic hilum was dis-
sected. A left extended hepatectomy including caudate
lobe with intrahepaticojejunostomy on the right ducts
of the liver was performed. Potential advantages of this
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procedure are the radicallity of the resection preserving
the benefits of the MIS approach.
In selected cases, a minimally invasive robotic approach
may allow safe extended hepatic resection with complex
reconstructions, respecting the oncological principles.
MVS3-1
RADICAL ANTERIOR MODULAR
PANCREATOSPLENECTOMY (RAMPS)
FOR PANCREAS BODY CANCER
Steven Martin Strasberg
Washington University in Saint Louis, U.S.A
Radical Anterior Modular Pancreatosplenectomy
(RAMPS) for pancreas body cancer.
Radical Antegrade Modular Pancreato-splenectomy
(RAMPS) is a relatively new modification of the stan-
dard distal pancreato-splenectomy . It was designed to
provide the operative approach developed for cancers
of the head of the pancreas to cancers of the body and
tail of the pancreas, particularly in respect to the extent
of node dissection and emphasis on obtaining micro-
scopically negative tangential margins . The three main
principles of the operation are, N1 lymph node dissec-
tion, modular setting of the posterior plane of dissec-
tion to optimize the opportunity to obtain negative
posterior margins, and right-to-left dissection to obtain
early vascular control. The depth of the posterior dis-
section is set preoperatively by study of computed to-
mograms. It is always behind the anterior renal fascia
but varies in respect to whether the adrenal gland and
Gerota’s fascia is removed. Staging laparoscopy is
always performed to rule out liver or peritoneal disease
prior to proceeding to laparotomy. In our long term
results in 47 patients negative tangential margins were
obtained in 89% of specimens, the overall R0 rate was
81%, mean lymph node count was 18, and there were
no 30 day or in-hospital mortalities. Mean and median
follow up times of living patients were 44.4 and 26.4
months. Median survival was 26 months and 5 year
overall actuarial survival was 35.5%. Others have
reported similar results with the procedure.
MVS3-2
DISTAL PANCREATECTOMY WITH
CELIAC AXIS RESECTION (DP-CAR)
FOR BORDERLINE RESECTABLE
PANCERAS BODY CANCER
Hiroki Yamaue
Wakayama Medical University School of Medicine,
Japan
The overall 5-year survival rates are generally less than
20% in patients with pancreatic carcinoma, even though
the patients have radical operation. Especially, the sur-
vival after surgery of patients with borderline resectable
pancreatic cancer is definitely worse and one should
consider the additional treatment for those patients-
subgroups, because radical surgical resection (R0)
remains the most important factor impacting the long-
term survival. The attempt for neoadjuvant approach
allowed for identification of a subset of patients who
were most likely to benefit from surgery, as evidenced
by the favorable median survival in this group. The
patients with favorable responses to preoperative ther-
apy (radiographic evidence of tumor regression and
improvement in serum tumor marker levels) were those
who had the best chance for R0 resection and a favorable
long-term survival. Moreover, most of the patients with
pancreatic body/tail carcinoma tend to be diagnosed in
more advanced stages, such as when there is tumor
involvement of the celiac axis (CA) and of the root of the
common hepatic artery (CHA). The indications for
distal pancreatectomy with en-bloc celiac axis resection
(DP-CAR) were extended recently to increase the R0
rate for advanced pancreatic body/tail carcinoma. How-
ever, one should consider whether the presence of just an
R0 resection should be the primary issue of cure in
borderline resectable pancreatic carcinoma, because most
pancreatic carcinomas recur systemically, and tumor
involving arterial structures recur rapidly even after the
complete resection. Therefore, it is well recognized that
neoadjuvant chemotherapy (NAC) or chemoradiothera-
py (NACRT) is essential for obtaining R0 resection in
patients with borderline resectable pancreatic cancer.
We have conducted the clinical trial for NAC using
gemcitabine and alternative day administration of S-1,
and the incidence of R0 reached 81% by NAC in bor-
derline resectable patients, whereas it was only 35%
without NAC treatment (Okada, Yamaue et al. Surgery
2013;153:365-372).
Surgical procedures: Our DP-CAR procedure basically
included en-bloc resection of the celiac, common hepatic,
and left gastric arteries, the celiac plexus, the left-sided
nerve plexus along the superior mesenteric artery
(SMA), a part of the crus of the diaphragm, and Gero-
ta’s fascia. In addition, the resection included the retro-
peritoneal fat tissues bearing lymph nodes above the
renal vein, the transverse mesocolon covering the body
of the pancreas, and the inferior mesenteric vein. Resec-
tion of the portal and the middle colic vessels and the left
adrenal gland was performed when necessary. In gen-
eral, no reconstruction of the arterial system was
required because of the early development of the collat-
eral arterial pathways via the pancreaticoduodenal
arcades from the superior mesenteric artery. Basically,
all our patients were expected to undergo preoperative
coil embolization of the CHA regardless of the diameter
of the gastroduodenal artery to enlarge the collateral
pathways and prevent ischemia-related complications.
How to reduce the incidence of delayed gastric empty-
ing after DP-CAR? Another problem of DP-CAR is a
delayed gastric emptying (DGE) due to the ischemic
gastropathy after resection of left gastric artery (LGA).
We have attempted preservation of LGA (modified
DP-CAR) if the patients have a tumor situated more
than 10mm away from the antecedent branching
LGA. The ISGPS grades of DGE were: no DGE =
43%, grade A = 26%, B = 13% and C = 17% in the
conventional DP-CAR group, and no DGE = 93%,
grade A = 7%, grade B/C = 0% in the modified DP-
CAR group. Thus, we conclude that Modified DP-
CAR significantly reduced the incidence of DGE in
comparison to conventional DP-CAR.
Surgical procedures of modified DP-CAR: Patients
whose LGA branched antecedently and who had a
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distance between the LGA and carcinoma greater than
10 mm underwent the modified DP-CAR, where the
artery was divided just after the branching of the LGA,
and after confirming that the patients were negative for
cancer cell infiltration into the nerve plexus surround-
ing the LGA by an intraoperative histopathological
diagnosis of several frozen sections.
In this video symposium, surgical procedures of 2
patients are shown including DP-CAR with and with-
out preservation of left gastric artery, and would like
to discuss the surgical procedures for patients with bor-
derline resectable pancreas body cancer.
MVS3-3
TOTAL PANCREATECTOMY FOR
BORDERLINE PANCREAS NECK
CANCER
Takashi Hatori
Tokyo Women’s Medical University, Japan
The pancreas neck cancer is worrisome cancer in terms
of the decision of the standard surgery because the
pancreatic neck is the arbitrary junction between the
head and body of the pancreas and portal vein lies
behind it. And the tumor is often a borderline resect-
able (BR) with portal vein invasion. Surgery in this
area often require removing a large portion of the nor-
mal pancreas by surgical procedures such as an
extended PD or a subtotal DP (removal of >80% of
the pancreas) or total pancreatectomy (TP) (in case of
pancreas neck cancer associating with intraductal
spreading of the tumor to the both directions (pancre-
atic head and tail)).
451 patients underwent pancreatectomy for the pancre-
atic ductal adenocarcinoma (PDAC) between 2000 and
2012. A total of 123 patients who included in the BR
pancreas neck PDAC were examined retrospectively.
66 patients underwent an extended PD and the positive
margin of the pancreatic stump was 9%. The operative
procedure was converted to the TP in 3 patients. 42
patients underwent a subtotal DP and the positive mar-
gin of the pancreatic stump was 7%. The operative
procedure was converted to the TP in one patient. The
remaining 15 patients underwent a TP and the patho-
logical examination revealed that 60% of the patients
underwent an adequate procedure, however, 27% of
the patients could be treated by an extended PD and
13% of the patients could be treated by a subtotal DP.
ATP is an aggressive option for BR pancreas neck
PDAC in case of the intraductal spreading of the
tumor to the both directions of the pancreatic head
and tail.
MVS3-4
TREATMENT OUTCOMES AND
STANDARDIZATION FOR OPTIMAL
CLINICAL TRIALS
Helmut Friess
Technische Universit€at M€unchen, Germany
Following curative resection and adjuvant chemother-
apy patients with pancreatic ductal adenocarcinoma
(PDAC) have a 5-year survival rate of 20%-25% and a
median survival of 17-28 months. This compares
favourable with the dismal prognosis of patients with
inoperable locally advanced, or metastatic disease that
have a median survival of 8-12 and 3-6 months, respec-
tively. Multiple series have shown that extended pan-
creatic resections for PDAC can be done with
comparable morbidity and mortality rates compared to
standard resections at specialised centres. Therefore,
extended resections are recommended by current guide-
lines in case of locally advanced or borderline PDAC
to improve survival. However, data from high-quality
clinical trials is lacking and frequently borderline
PDAC patients cannot be resected.
Evaluating borderline PDAC in clinical trials raises sev-
eral problems. As there is no universally accepted defi-
nition of borderline PDAC and inclusion criteria in
available clinical trials are often not standardized.
Depending on the definition employed, reported rates
of borderline PDAC vary between 10%-25%. Border-
line definitions should consider: a) the absence of dis-
tant metastasis, b.) involvement of the portal vein and
the superior mesenteric vein, c.) involvement of the gas-
troduodenal and hepatic artery and d.) involvement of
the superior mesenteric artery. An acceptable definition
of bordeline resectability well suited for clinical trials
has been proposed by an international consensus con-
ference and has been adopted by the U.S. National
Comprehensive Cancer Network.
As resected borderline PDAC patients are at high-risk
for margin-positive resections and early treatment fail-
ure following a surgery-first strategy, neoadjuvant strat-
egies are increasingly employed. However, response
evaluation is difficult due to the extensive desmoplastic
reactions in PDAC, which impedes radiologic/morpho-
logic evaluation. Functional response evaluation proce-
dures like FDG-PET have rendered conflicting results
and are not yet standardized, while cytologic/histologic
response evaluation seems impractical due to the ana-
tomic difficulties in obtaining biopsies from the tumour
and the high rate of false negative biopsies due to the
stromal reaction. Furthermore, choosing clinically
meaningful endpoints in borderline PDAC trials is
challenging. While some authors propose R1-resection
rate as a feasible endpoint in clinical trials as it has
been shown to be a prognostic factor in some trials
others have failed to do so, mainly because margin
clearance is largely dependent on the pathological han-
dling and reporting of specimens. Following the imple-
mentation of standardized pathologic protocols, R1
resection rates of up to 75%-85% have been reported.
Similarly, the ratio of resected/unresected patients in a
RCT seems inappropriate, as the surgical decision mak-
ing, the number of treatment failures in the neoadju-
vant arm and the lack of blinding makes it prone to
bias. Therefore, endpoints in borderline PDAC trials
should be, from a clinical and methodological perspec-
tive, as persuasive as for other oncology trials. Regula-
tory institutions like the European Medicines Agency
(EMA) or the U.S. Food and Drug Administration
(FDA) have unanimously published position papers in
which overall survival (OS), progression free survival
(PFS) and disease-free survival (DFS) have been pro-
posed as suitable efficacy endpoints. Furthermore, all
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trials should address translational aspects. Modern trial
designs with combined phase II/III trials or with adap-
tive trial designs should be considered to accelerate
progress.
Finally, the advent of effective chemotherapeutic
regimes against PDAC allows to address the important
aspect of patient selection. Induction chemotherapy
may be used as an appropriate tool to define borderline
PDAC patients who may benefit most from subsequent
resection with or without previous radiotherapy.
MVS3-5
ISOLATED
PANCREATODUODENECTOMY
COMBINED WITH PORTAL VEIN
RESECTION FOR BORDERLINE
RESECTABLE PANCREAS HEAD
CANCER
Akimasa Nakao
Nagoya Central Hospital, Japan
Basic radical surgery for pancreatic head cancer is iso-
lated pancreatoduodenectomy (PD). Isolated means the
non-touch isolation technique. The two important com-
ponents of isolated PD for borderline resectable pan-
creatic cancer are the mesenteric (Nakao) approach
and catheter (Nakao) bypass of the portal vein.
In this video presentation two types of aggressive sur-
gery for borderline resectable pancreatic head cancer
are introduced using our procedures.
The 1st case: pancreatic head cancer invaded the pos-
terior wall of the SMV and the posterior side of the
SMA at 270 degrees of the circumference of the vessel.
The first step of this operation is the mesenteric
approach. Kocher’s maneuver is not performed. The
incision of the mesenterium from the Treitz ligament to
the lower border of the second portion of the duode-
num is made. All connective tissues around the SMA
and SMV including lymph nodes and nerve plexus
around the SMA are dissected toward the lower border
of the pancreatic head and the IPDA is then ligated
and divided. By this procedure the cancer-free surgical
margin is obtained and resectability is decided. Then,
the operative procedure is moved to the hepatic hilus,
and the lymph node clearance of the hepatoduodenal
ligament and around the CHA are done. The GDA is
then ligated and divided. The invaded SMV is resected
and the reconstruction of SMV using end-to-end anas-
tomosis is done under the SMA clamp. 2nd case: pan-
creatic head cancer invaded the SMV, PV and SV. The
PV obstruction was observed. The SMA was not
invaded. Isolated PD combined with PV, SMV and SV
resection is done. To avoid portal congestion during
the operation, an antithrombogenic catheter-bypass is
employed between one branch of the SMV and the
right femoral vein via right the greater saphenous vein.
The nerve plexus around the SMA was preserved. The
reconstruction of the portal vein was done by end-to-
end anastomosis between the portal and superior mes-
enteric veins.
Isolated pancreatoduodenectomy combined with portal
vein resection for borderline resectable pancreatic head
cancer is done with safety and ease using mesenteric
approach and catheter-bypass of the portal vein.
Pancreatic cancer, Borderline resectable pancreatic can-
cer, Portal vein resection, Mesenteric approach, Cathe-
ter-bypass of the portal vein
MVS4-1
LAPAROSCOPIC SURGERY FOR
CHOLEDOCHAL CYST
Jin-Young Jang
Seoul National University Hospital, Korea
In spite of a benign disease, a choledochal cyst must be
removed with the gallbladder (GB) due to the risk of
cancer in the biliary tract. Most patients are young
females or children, all of whom express strong interest
in the cosmetic results in addition to the complete reso-
lution of their medical problems. Here, we introduce a
laparoscopic management technique for a choledochal
cyst.
Between 2003 and 2013, we performed a laparoscopic
choledochal cyst excision procedure on 103 patients
using a four-hole method. There were three open-
conversion cases, one case involving robotic surgery, and
one case involving combined laparoscopic liver resection
because the cyst had affected the liver. Excision of the
cyst and anastomosis were performed laparoscopically.
We will present our method with a video.
The mean operation time was 213 min. The estimated
blood loss was 175 ml. The average hospital stay was
7.9 days. The most common complications were minor
bile leakage (5 %) and fluid collection (2.7 %), both of
which were managed conservatively.
Laparoscopic management can be a treatment of choice
for the most instances of choledochal cyst considering
its good cosmetic results and its feasible level of opera-
tive safety.
MVS4-2
LAPAROSCOPIC SURGERY FOR CBD
STONE
Leslie K. Nathanson
MBCh.B FRACS FRCS, Australia
Laparoscopic bile duct exploration simplifies pre-opera-
tive investigations to US and LFTs and selective MRI
or CT cholangiogram. Two of every three patients will
avoid choledochotomy or ERCP with this approach
which provides the patient a one stage procedure to
solve their problem and results in cost savings of 40%.
There may also be benefit of a lower incidence of
ampullary strictures in the long term. Although this is
an area for which there are little data, the clinical bene-
fits of avoiding potential ERCP sphincter damage and
late re-stenosis (reported in up to 20% of patients fol-
lowed for 20 years), may only become apparent after
many years.
Newer techniques may simplify choledochoscopic
access and treatment of difficult and impacted stones
and will be demonstrated in detail.
It is my view that the clinical and cost benefits should
persuade biliary surgeons to develop their skills of lapa-
roscopic bile duct clearance. Performance should be
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monitored by constant audit of outcome. If this does
not match the outcomes of the published trials, further
training should be sought to develop the expertise.
MVS4-3
LAPAROSCOPIC TREATMENT FOR
IHD STONES
Chung Ngai Tang
Pamela Youde Nethersole Eastern Hospital, China
Primary hepatolithiasis is formed de novo in the intra-
hepatic ducts (IHD) and is a distinct disease entity char-
acterized by repeated primary bacterial infection with
subsequent formation of multiple stones and strictures
in any part of the biliary tract. The disease was first
described by Digby in Hong Kong back to 1930 and it
then came to be known as recurrent pyogenic cholangi-
tis (RPC). It is a prevalent disease in Southeast Asia,
but rare in Western countries. The management of pri-
mary hepatolithiasis is multidisciplinary, aiming to
remove all biliary stones, to establish adequate biliary
drainage, and to resect nonfunctioning liver segments
which harbor bacteria and serve as foci of infection.
The development of minimally invasive surgery over
the last two decades has a great impact on the surgical
practice. With the wide application of laparoscopic sur-
gery in biliary diseases, laparoscopic bile duct explora-
tion has been one of the main treatment methods for
common bile duct (CBD) stones. The technique for
stone removal in the CBD could also be applied to
IHD stones. However, due to the technical difficulty,
reports of laparoscopic treatment for IHD stones have
been rare. On the other hand, laparoscopic liver resec-
tion also becomes possible with the availability of new
instruments that allow a relatively bloodless liver tran-
section. The potential advantages of laparoscopic liver
resection are those of minimally invasive surgery, such
as early recovery, shorter hospital stay, lower incidence
of wound complications, and better cosmetic outcome.
Conventional laparoscopic liver resection has been
shown to be as safe and feasible in experienced hands.
However, the restrictive movement of laparoscopic
instruments, limited by fixed pivot point with only 4
degree of freedom and 2-dimensional view, limits its
utility in hepatobiliary surgery with a complex reper-
toire of operations. Robotic surgery has the potential
to alleviate the inherent limitations of laparoscopic sur-
gery such as two dimensional imaging, limited instru-
ment movement and intrinsic human tremor.
The aim of the presentation is to show different laparo-
scopic techniques in the treatment of primary hepato-
lithiasis.
MVS4-5
LAPAROSCOPIC SURGERY FOR
EXTRAPANCREATIC
CHOLANGIOCARCINOMA
Andrew Gumbs
Columbia University College of Physicians and
Surgeons, U.S.A.
Due to the perceived difficulty in dissecting gallbladder
cancers and extrapancreatic cholangiocarcinomas off of
the portal structures and in performing complex biliary
reconstructions, very few centers have used minimally
invasive techniques to remove these tumors. Further-
more, due to the relative rarity of these tumors when
compared to hepatocellular carcinoma, only a few
reports have focused on short- and long-term results.
We performed a review by combining the experience of
three international centers with expertise in complex
minimally invasive hepatobiliary surgery. Patients were
entered into a database prospectively. All patients with
gallbladder cancer and cholangiocarcinoma were ana-
lyzed; patients with distal cholangiocarcinomas who
underwent laparoscopic pancreatoduodenectomies were
excluded. Patients were divided according to if they
had gallbladder cancer, hilar cholangiocarcinoma, or
intrahepatic cholangiocarcinoma.
A total of 15 patients underwent laparoscopic resection
for gallbladder cancer and 10 for preoperatively sus-
pected gallbladder cancer, and 5 underwent laparo-
scopic completion procedures. An average of four
lymph nodes (range = 1-11) were retrieved and all
patients had an R0 resection. One patient (7 %)
required conversion to an open procedure. No patients
developed a biliary fistula, required percutaneous drain-
age, or had endoscopic stent placement. One patient
had a recurrence at 3 months despite a negative final
pathological margin, and a second patient had a distant
recurrence at 20 months with a mean follow-up of 23
months. Nine patients underwent laparoscopic hepatec-
tomy for intrahepatic cholangiocarcinoma. All anasto-
moses were completed laparoscopically. Biliary fistula
was seen in two patients, one of which died after a
transhepatic percutaneous biliary drain resulted in
uncontrollable intra-abdominal hemorrhage despite re-
operation. A third patient developed a pulmonary
embolism. Thus, the morbidity and mortality rates were
33 and 11 %, respectively. One patient was converted
to open and six patients (66 %) are alive with a median
follow-up of 22 months. Five patients underwent mini-
mally invasive resection for hilar cholangiocarcinoma;
of these, two also required laparoscopic major hepatec-
tomy. The mean estimated blood loss (EBL) was 240
mL (range = 0-400 mL) and the median length of stay
(LOS) was 15 days (range = 11-21 days). All patients
are alive with a median follow-up of 11 months (range
= 3-18 months). None of the 29 patients developed port
site recurrences.
Minimally invasive approaches to gallbladder cancer
and intrahepatic and extrahepatic cholangiocarcinoma
seem feasible and safe in the short term. Larger series
with longer follow-up are needed to see if there are any
long-term disadvantages or advantages to laparoscopic
resection of extrapancreatic cholangiocarcinoma.
MVS4-6
TOTALLY LAPAROSCOPIC HEPATO-
PANCREATO-DUODENECTOMY FOR
DIFFUSE BILE DUCT CANCER
Akihiro Cho
Chiba Cancer Center Hospital, Japan
Only complete tumor resection enables the long-term
survival for patients with cholangiocarcinoma, and
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary Association HPB 2014, 16 (Suppl. 2), 59–67
66 Master Video Symposium
major hepatic resection or pancreaticoduodenectomy
(PD) is often required to obtain curative surgical resec-
tion. Hepato-pancreaticoduodenectomy (HPD) has
been offered as a surgical option for selected patients
with cholangiocarcinoma showing widespread infiltra-
tion. Minimally invasive surgery has been widely
accepted as an alternative to conventional open surgery
in many gastrointestinal fields, even for malignancy.
Recent technological developments and improved endo-
scopic procedures have greatly enlarged the application
of laparoscopic liver or pancreatic resection. A wide
variety of laparoscopic major liver or pancreatic resec-
tions, including hemihepatectomy or pancreaticoduo-
denectomy, have been performed. The report describes
our recent experience with pure laparoscopic HPD,
including left hepatectomy, caudate lobectomy, and
pylrous-preserving pancreaticoduodenectomy, for cho-
langiocarcinoma with a successful outcome.
First, a pylrous-preserving pancreaticoduodenectomy
was performed as previously described. The neck of the
pancreas was separated from the superior mesenteric
and portal vein, and the pancreatic neck was transect-
ed. The proximal jejunum and duodenum was thor-
oughly dissected. The proximal jejunum was transected
and the end of the jejunum was delivered into the right
of the superior mesenteric vessels. A dissection between
the pancreatic head and the superior mesenteric vessels
was performed. The common bile duct was lifted in the
cranio-ventral direction and skeletonization of the
hepatic artery and portal vein was advanced up to the
hepatic hilum. The root of the left hepatic artery was
divided, and the right anterior and right posterior sec-
tional arteries were skeletonized. The portal trunk and
portal bifurcation were skeletonized, and the root of the
left portal vein was divided. The left liver was mobilized
to the right, and the minor omentum was opened. The
Arantius ligament was divided. The short hepatic veins
between the dorsal surface of the caudate lobe and infe-
rior vena cava (IVC) were divided following division of
the left IVC ligament to mobilize the left caudate lobe
(Spiegel lobe). The caudate lobe was fully separated from
the IVC. Liver parenchymal transection began from the
caudal-ventral edge of the demarcation line and was per-
formed along the middle hepatic vein. The direction of
parenchymal dissection proceeded toward the right edge
of the IVC. The intrahepatic arterial branches were sepa-
rated from the bile ducts, and the right anterior and pos-
terior sectional bile ducts were divided respectively.
Finally, the left hepatic vein was divided, and the speci-
men was placed in a plastic endobag, and extracted
through a navel incision, which was extended to 5 cm.
The proximal jejunal end was delivered through a
window in the transverse mesocolon. Child’s method of
reconstruction, which included an end-to-side pancreat-
icojejunostomy, an end-to-side hepaticojejunostomy,
and an end-to-side duodenojejunostomy in a proximal-
to-distal manner, were performed. The end-to-side hepa-
ticojejunostomy was performed with running suture, and
the end-to-side pancreaticojejunostomy was performed
using mattress sutures intracorporeally. Two drainage
tubes were placed under the hepaticojejunostomy and
over the pancreatic anastomosis, respectively.
The procedure took 629 minutes and there was minimal
blood loss, so no blood transfusion was required. The
nasogastric tube was removed on the following day.
Oral intake was initiated on the 4th postoperative day.
The abdominal drainage tube was removed on the 28th
postoperative day because the patient had developed
biliary leakage that later resolved spontaneously. The
patient was discharged on the 32th postoperative day.
A histological examination showed well differentiated
tubular adenocarcinoma. Although the tumor had
widely infiltrated to the intra- and extrahepatic bile
duct, the surgical margins were histologically clear (R0
resection).
Although the experience is limited and it is difficult to
obtain a large series of this extremely aggressive proce-
dure, laparoscopic HPD can be feasible, safe, and effec-
tive in highly selected patients. However, the benefits of
this procedure remain to be proven. Obviously, not only
adequate experience in hepato-biliary and pancreatic
surgery, but also expertise in laparoscopy is mandatory
and the careful selection of patients is also essential for
the successful application of this procedure.
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